Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma

Yang,Yongping; Lu,Yinying; Wang,Chunping; Bai,Wenlin; Qu,Jianhui; Chen,Yan; Chang,Xiujuan; An,Linjing; Zhou,Lin; Zeng,Zhen; Lou,Min; Lv,Jiyun

doi:10.3892/etm.2011.398

Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma

Authors:
- Yongping Yang
- Yinying Lu
- Chunping Wang
- Wenlin Bai
- Jianhui Qu
- Yan Chen
- Xiujuan Chang
- Linjing An
- Lin Zhou
- Zhen Zeng
- Min Lou
- Jiyun Lv
View Affiliations

Affiliations: Center of Therapeutic Research for Hepatocellular Carcinoma, Beijing 302nd Hospital, Beijing 100039, P.R. China
Published online on: December 1, 2011 https://doi.org/10.3892/etm.2011.398
Pages: 171-180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib may prolong survival in patients with advanced hepatocellular carcinoma (HCC), but with limited efficacy. The present study aimed to assess the safety and efficacy of sorafenib combined with cryotherapy (cryoRx) for the treatment of advanced HCC. A total of 104 patients met the following criteria: advanced HCC without distant metastasis, presence of portal vein thrombosis, Child-Pugh class A or B and life expectancy of at least 12 weeks. All patients were randomly assigned to sorafenib and cryoRx (n=52) or sorafenib-alone (n=52) treatment groups. The primary end-point of the study was overall survival (OS). The secondary end-points included time to progression (TTP) and tolerability. Microvessel density (MVD) was assessed following immunostaining for CD34. In a median of 10.5 (4-26) months follow-up, the median OS was 12.5 months (95% CI 10.6-16.4) in the combination therapy vs. 8.6 months (7.3-10.4) in the sorafenib-alone (P=0.01) group. The median TTP was 9.5 months (8.4‑13.5) in the combination therapy vs. 5.3 months (3.8-6.9) in the sorafenib alone (P=0.02) group. CryoRx was an independent factor associated with improved clinical outcomes of sorafenib for the treatment of advanced HCC. Patients with low intratumoral MVD receiving the combination therapy exhibited a significantly longer median TTP and OS compared to those receiving sorafenib. High intratumoral MVD was an independent predictor of poor responses to sorafenib for advanced HCC. Compared with previous reports of sorafenib-related adverse drug reactions (ADRs), cryoRx did not further increase the frequency and degree of sorafenib-related ADRs. In conclusion, compared to sorafenib alone, the addition of cryoRx to sorafenib significantly improves the clinical outcomes of sorafenib for the treatment of advanced HCC with acceptable tolerance and similar safety profiles as previously reported. High intratumoral MVD is predictive of poor responses to sorafenib in advanced HCC patients.

View Figures

View References

1.	DM ParkinGlobal cancer statistics in the year 2000Lancet Oncol253343200111905707
2.	ZY TangPerspective of clinical onology from the viewpoint of liver cancer studiesTumor (China)29142009
3.	HY YooCH PattJF GeschwindThe outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with timeJ Clin Oncol2143294335200314581446
4.	HI YangSN LuYF LiawSL YouCA SunLY WangCK HsiaoPJ ChenDS ChenCJ ChenHepatitis B e antigen and the risk of hepatocellular carcinomaN Engl J Med347168174200210.1056/NEJMoa01321512124405
5.	M ShermanHepatocellular carcinoma: epidemiology, risk factors, and screeningSemin Liver Dis25143154200510.1055/s-2005-87119415918143
6.	JM LlovetA BurroughsJ BruixHepatocellular carcinomaLancet36219071917200310.1016/S0140-6736(03)14964-1
7.	JM LlovetA BurroughsJ BruixPrognosis of hepatocellular carcinoma: the BCLC staging classificationSemin Liver Dis19329338199910.1055/s-2007-100712210518312
8.	J BruixJM LlovetPrognosis prediction and treatment strategy in hepatocellular carcinomaHepatology35519524200210.1053/jhep.2002.3208911870363
9.	J BruixM ShermanManagement of hepatocellular carcinomaHepatology4212081236200510.1002/hep.20933
10.	KW ParkJW ParkJI ChoiSurvival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic areaJ Gastroenterol Hepatol23467473200810.1111/j.1440-1746.2007.05112.x17764529
11.	JM LlovetJ FusterJ Bruixthe Barcelona-Clinic Liver Cancer GroupThe Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinomaLiver Transpl10Suppl 1115120200410.1002/lt.2003414762851
12.	AL ChengYK KangZ ChenRandomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinomaLancet Oncol102534200910.1016/S1470-2045(08)70285-7
13.	JM LlovetS RicciV MazzaferroSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med359378390200810.1056/NEJMoa070885718650514
14.	J FuruseSorafenib for the treatment of unresectable hepatocellular carcinomaBiologics2779788200819707458
15.	A HakiméA Hines-PeraltaH PeddiCombination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in miceRadiology244464470200717641366
16.	S OsadaH ImaiH TomitaSerum cytokine levels in response to hepatic cryoablationJ Surg Oncol95491498200710.1002/jso.2071217219394
17.	G PostonCryosurgery for colorectal liver metastasesHepatogastroenterol48323324200111379300
18.	FT Lee JrDM MahviSG ChosyGM OnikWS WongPJ LittrupKA ScanlanHepatic cryosurgery with intraoperative US guidanceRadiology202624632199710.1148/radiology.202.3.90510059051005
19.	SA ShockPF LaesekeLA SampsonWD LewisTC Winter IIIJP FineFT LEE JrHepatic hemorrhage caused by percutaneous tumor ablation: radiofrequency ablation versus cryoablation in a porcine modelRadiology236125131200510.1148/radiol.236104053315987968
20.	TD AtwellMA FarrellMR CallstromJW CharboneauBC LeibovichDE PattersonGK ChowML BlutePercutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experienceRadiology24327683200710.1148/radiol.243105213317329689
21.	W JungraithmayrD BurgerM OlschewskiS EggsteinCryoablation of malignant liver tumor: results of a single center studyHepatobiliary Pancreat Dis Int4554560200516286261
22.	J YamamotoT KosugeA SaiuraEffectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan CriteriaJpn J Clin Ocncol34287295200710.1093/jjco/hym025
23.	R LencioniJM LlovetModified RECIST (mRECIST) assessment for hepatocellular carcinomaSemin Liver Dis305260201010.1055/s-0030-124713220175033
24.	A TrottiAD ColevasA SetserCTCAE v 3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSemin Radiat Oncol13176181200310.1016/S1053-4296(03)00031-6
25.	C WangY LuY ChenY FengL AnX WangS SuW BaiL ZhouY YangD XuPrognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective studyClin Exp Metastasis26839848200910.1007/s10585-009-9283-619784786
26.	RT PoonIO NgC LauWC YuZF YangST FanJ WongTumor microvessel density as a predictor recurrence after resection of hepatocellular carcinoma: a prospective studyJ Clin Oncol2017751785200210.1200/JCO.2002.07.08911919234
27.	T YauP ChanKK NgPhase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor responseCancer115428436200910.1002/cncr.24029
28.	TF GretenF KorangyMP MannsNP MalekMolecular therapy for the treatment of hepatocellular carcinomaBr J Cancer1001923200910.1038/sj.bjc.660478419018262
29.	LM ZuroED StarenCryosurgical ablation of unresectable hepatic tumorsAORN J6423162394419968853781
30.	T ShimizuY SakuharaD AboY HasegawaY KodamaH EndoH ShiratoK MiyasakaOutcome of MR-guided percutaneous cryoablation for hepatocellular carcinomaJ Hepatobiliary Pancreat Surg16816823200910.1007/s00534-009-0124-419466377
31.	JH ShimJW ParkJI ChoiBJ ParkCM KimPractical efficacy of sorafenib monotherapy for advanced hepatocellular carcnoma patients in a Hepatitis B virus-endemic areaJ Cancer Res Clin Oncol135617625200910.1007/s00432-008-0496-x18846384
32.	M PinterW SieghartI GraziadeiW VogelA MaieronR KönigsbergA WeissmannG KornekC PlankM Peck-RadosavljevicSorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosisOncologist147076200910.1634/theoncologist.2008-019119144684
33.	RC KaneAT FarrellR MadabushiSorafenib for the treatment of unresectable hepatocellular carcinomaOncologist1495100200910.1634/theoncologist.2008-018519144678
34.	J FuruseH IshiiK NakachiPhase I study of sorafenib in Japanese patients with hepatocellular carcinomaCancer Sci99159165200817953709
35.	MA WörnsA WeinmannK PfingstSafety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisJ Clin Gastroenterol43489495200919247201
36.	B VincenziD SantiniA RussoEarly skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibOncologist158592201010.1634/theoncologist.2009-014320051477
37.	C SchrammG SchuchAW LohseSorafenib-induced liver failureAm J Gastroenterol10321622163200810.1111/j.1572-0241.2008.01982_19.x18796127
38.	D SemelaJF DufourAngiogenesis and hepatocellular carcinomaJ Hepatol41864880200410.1016/j.jhep.2004.09.00615519663
39.	L LiuY CaoC ChenSorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5Cancer Res661185111858200610.1158/0008-5472.CAN-06-137717178882
40.	M LiH LiC LiL GuoH LiuS ZhouX LiuZ ChenS ShiJ WeiMA McNuttG LiCytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cellsCancer Lett285190199200910.1016/j.canlet.2009.05.01419501957
41.	M LiH LiC LiS ZhouL GuoH LiuW JiangX LiuP LiMA McNuttG LiAlpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cellsInt J Cancer12428452854200910.1002/ijc.2427219267404